{"disease":{"id":"plaque-type-psoriasis","name":"plaque type psoriasis"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT01544595","title":"Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1147,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT02474069","title":"Secukinumab Dosage Optimisation in Partial Responders With Moderate to Severe Plaque-type Psoriasis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":772,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT02074982","title":"Efficacy of Secukinumab Compared to Ustekinumab in Patients With Plaque-type Psoriasis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":676,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT01640951","title":"4 Year Extension Study of Efficacy and Safety of Secukinumab in Patients With Moderate to Severe Chronic Plaque-type Psoriasis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":675,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT02660580","title":"MSB11022 in Moderate to Severe Chronic Plaque Psoriasis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":443,"lead_sponsor_name":"Fresenius Kabi SwissBioSim GmbH","has_results":true},{"nct_id":"NCT00773734","title":"Efficacy and Safety Study of Apremilast (CC-10004) in Subjects With Moderate-to-Severe Plaque-Type Psoriasis (Core Study)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":352,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT03504852","title":"Efficacy and Safety of 2 Secukinumab Regimens in 90kg or More Weight Group With Moderate/Severe Chronic Plaque Psoriasis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":331,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT01132612","title":"AIN457 Regimen Finding Extension Study in Participants With Moderate to Severe Psoriasis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":275,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT01636687","title":"Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":182,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT01555125","title":"First Study of Secukinumab in Pre-filled Syringes in Subjects With Chronic Plaque-type Psoriasis: Response at 12 Weeks","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":177,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT02471144","title":"Pediatric Study in Children and Adolescents With Severe Plaque Psoriasis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":162,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT04207801","title":"A Phase II Study to Evaluate Efficacy & Safety of AUR101 in Patients of Moderate-to-Severe Psoriasis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":90,"lead_sponsor_name":"Aurigene Discovery Technologies Limited","has_results":true},{"nct_id":"NCT03668613","title":"Study to Assess the Long-term Safety, Tolerability, Efficacy of Secukinumab in Pediatric Patients of Age 6 to <18 Years, With Moderate to Severe Plaque Psoriasis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":84,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT03553823","title":"Comparison of Secukinumab Versus Guselkumab in Clearing Psoriatic Plaques Refractory to Ustekinumab","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":40,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT00521339","title":"Apremilast Safety and PK Study in Recalcitrant Plaque Psoriasis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":31,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT01258088","title":"Safety Study of Ointment for the Treatment of Plaque-type Psoriasis","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":16,"lead_sponsor_name":"Pfizer","has_results":false}],"total":16},"guidelines":[],"source":"Drug Landscape verified database"}